Jessica A Fleming

Affiliate Assistant Professor, Epidemiology



PhD Epidemiology, University of Washington, 2009
MSc Tropical Public Health, Harvard T.H. Chan School of Public Health, 1998
BS Biology, Wake Forest University, 1990



2001 Westlake Avenue, Suite 200
PO Box 900922
Seattle, WA 98109
View Website »


Jessica Fleming is a Product Development Director and the Maternal Immunization Delivery Lead in the Policy, Access and Introduction program within PATH’s Center for Vaccine Introduction and Access. With over twenty five years of experience working in international public health, she provides public health leadership in evaluating the impact of vaccines and health technologies appropriate for low resource settings and generating evidence to assist countries in preparing for new vaccine introduction. Dr. Fleming currently leads the Advancing Maternal Immunization (AMI) collaboration that enables efficient, well-informed decisions around the introduction of maternal immunizations in low- and middle-income countries, with a special emphasis on maternal vaccines for respiratory syncytial virus. She leads formative research on maternal vaccine decision-making and acceptance. Her work includes conducting clinical studies to quantify the impact of vaccines and improve their performance in low-income populations and contributing to global guidance on the use of safe injection technologies and waste management. Before joining PATH in 2003, Dr. Fleming lived and worked in a number of complex emergency and humanitarian relief settings in Africa and Asia. Dr. Fleming holds a Doctorate of Philosophy in epidemiology from the University of Washington and a Master of Science in tropical public health from the Harvard School of Public Health with a concentration in infectious disease epidemiology and international health. She is an affiliate assistant professor in the Epidemiology Department at the University of Washington.

Research Interests

Maternal immunization, Vaccine policy making; Vaccine evaluation; increasing access to health technologies in low resource settings

Recent Publications (PubMed)

Reassessing potential economic value and health impact of effective Shigella vaccines.
(2024 Jan 1)
Bull World Health Organ 102(1): 65-74
Hausdorff WP, Anderson JD 4th, Bourgeois AL, Clifford A, Fleming JA, Muhib F, Pecenka C, Puett C, Riddle MS, Scheele S, Bagamian KH

Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022.
(2023 Nov 22)
Vaccine 41(48): 7047-7059
Fitzpatrick MC, Laufer RS, Baral R, Driscoll AJ, Feikin DR, Fleming JA, Jit M, Kim S, Koltai M, Li Y, Li X, Nair H, Neuzil KM, Pecenka C, Sparrow E, Srikantiah P, Ortiz JR

Exploring Shigella vaccine priorities and preferences: Results from a mixed-methods study in low- and middle-income settings.
(2023 Dec)
Vaccine X 15(): 100368
Fleming JA, Gurley N, Knudson S, Kabore L, Bawa JT, Dapaah P, Kumar S, Uranw S, Tran T, Mai LTP, Odero C, Obong'o C, Aburam K, Wanjiru S, Hanh NTM, Dung LP, Hausdorff WP

Value profile for respiratory syncytial virus vaccines and monoclonal antibodies.
(2023 Nov 3)
Vaccine 41 Suppl 2(): S7-S40
Fleming JA, Baral R, Higgins D, Khan S, Kochar S, Li Y, Ortiz JR, Cherian T, Feikin D, Jit M, Karron RA, Limaye RJ, Marshall C, Munywoki PK, Nair H, Newhouse LC, Nyawanda BO, Pecenka C, Regan K, Srikantiah P, Wittenauer R, Zar HJ, Sparrow E

Respiratory Syncytial Virus (RSV) Disease and Prevention Products: Knowledge, Attitudes, and Preferences of Kenyan Healthcare Workers in Two Counties in 2021.
(2023 Jun 2)
Vaccines (Basel) 11(6):
Nyawanda BO, Opere VA, Nyiro JU, Vodicka E, Fleming JA, Baral R, Khan S, Pecenka C, Ayugi JO, Atito R, Ougo J, Bigogo G, Emukule GO, Otieno NA, Munywoki PK

Show complete publication list

In the News

No news articles at this time.